Exelixis, GSK bring partnership to scheduled end

SOUTH SAN FRANCISCO, Calif. Exelixis announced Friday that its partnership with GlaxoSmithKline will end Oct. 27, as scheduled.

Under the terms of the partnership, GSK can select two of the compounds that the companies developed for further development and marketing. Exelixis will have the right to further develop any compound that GSK doesn’t select. Exelixis generated 10 compounds and earned more than $235 million.

The two companies began the partnership in October 2002 to create drugs for vascular biology, inflammatory disease and cancer.